These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12570953)

  • 1. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.
    Nielsen OW; McDonagh TA; Robb SD; Dargie HJ
    J Am Coll Cardiol; 2003 Jan; 41(1):113-20. PubMed ID: 12570953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
    Vasan RS; Benjamin EJ; Larson MG; Leip EP; Wang TJ; Wilson PW; Levy D
    JAMA; 2002 Sep; 288(10):1252-9. PubMed ID: 12215132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography.
    Ng LL; Loke I; Davies JE; Khunti K; Stone M; Abrams KR; Chin DT; Squire IB
    Eur J Heart Fail; 2003 Dec; 5(6):775-82. PubMed ID: 14675856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography.
    Sim V; Hampton D; Phillips C; Lo SN; Vasishta S; Davies J; Penney M
    Fam Pract; 2003 Oct; 20(5):570-4. PubMed ID: 14507800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?
    Galasko GI; Barnes SC; Collinson P; Lahiri A; Senior R
    Eur Heart J; 2006 Jan; 27(2):193-200. PubMed ID: 16267076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNP in the community - still work to be done..
    Rao A; Hodgson L; Pearce D; Walsh J
    Int J Cardiol; 2008 Feb; 124(2):228-30. PubMed ID: 17363081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical detection of left-ventricular systolic dysfunction.
    McDonagh TA; Robb SD; Murdoch DR; Morton JJ; Ford I; Morrison CE; Tunstall-Pedoe H; McMurray JJ; Dargie HJ
    Lancet; 1998 Jan; 351(9095):9-13. PubMed ID: 9433422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction.
    Krüger S; Filzmaier K; Graf J; Kunz D; Stickel T; Hoffmann R; Hanrath P; Janssens U
    J Intern Med; 2004 Feb; 255(2):206-12. PubMed ID: 14746557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women.
    Hedberg P; Lönnberg I; Jonason T; Nilsson G; Pehrsson K; Ringqvist I
    Am Heart J; 2004 Sep; 148(3):524-9. PubMed ID: 15389243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide.
    Freitag MH; Vasan RS
    Heart Fail Monit; 2003; 4(2):38-44. PubMed ID: 14724717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.
    Heidenreich PA; Gubens MA; Fonarow GC; Konstam MA; Stevenson LW; Shekelle PG
    J Am Coll Cardiol; 2004 Mar; 43(6):1019-26. PubMed ID: 15028361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction.
    Atisha D; Bhalla MA; Morrison LK; Felicio L; Clopton P; Gardetto N; Kazanegra R; Chiu A; Maisel AS
    Am Heart J; 2004 Sep; 148(3):518-23. PubMed ID: 15389242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention.
    Świątkiewicz I; Magielski P; Woźnicki M; Gierach J; Jabłoński M; Fabiszak T; Koziński M; Sukiennik A; Bronisz A; Kubica J
    Kardiol Pol; 2012; 70(4):329-40. PubMed ID: 22528703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of BNP for an early diagnosis of asymptomatic left ventricular dysfunction: a retrospective study.
    De Vecchis R; Esposito C; Ariano C; Di Biase G
    Minerva Cardioangiol; 2014 Apr; 62(2):147-59. PubMed ID: 24686994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care].
    Lobos Bejarano JM; Horrillo García C; González-González AI; Castellanos Rodríguez A; Díaz Sánchez S; Castellanos Maroto J; Rodriguez-Barrientos R; García-Fernández MA
    Aten Primaria; 2012 Jan; 44(1):13-9. PubMed ID: 21636177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of B-type natriuretic peptide testing.
    Mueller C
    Congest Heart Fail; 2008; 14(4 Suppl 1):35-7. PubMed ID: 18772637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.